FDA Proposes Study to Improve DTC Print Ad Disclosures

Drug Industry Daily
A A
The FDA is proposing an experimental study to examine the effects of risk disclosures and fine print in direct-to-consumer drug advertising.

To View This Article:

Login

Subscribe To Drug Industry Daily